TABLE 2.
Base-Case Results
| Pazopanib | Sunitinib | Difference | |
|---|---|---|---|
| Effectiveness (not discounted), $ | |||
| Progression-free life-years | 1.130 | 1.147 | -0.017 |
| Postprogression life-years | 0.993 | 0.921 | 0.072 |
| Life-years | 2.122 | 2.068 | 0.054 |
| QALYs | 1.393 | 1.301 | 0.092 |
| Effectiveness (discounted), $ | |||
| Progression-free life-years | 1.113 | 1.130 | -0.016 |
| Postprogression life-years | 0.957 | 0.887 | 0.069 |
| Life-years | 2.070 | 2.017 | 0.053 |
| QALYs | 1.361 | 1.270 | 0.090 |
| Costs (discounted), $ | |||
| Study medication | 68,209 | 74,473 | -6,264 |
| Administration/dispensing | 1,008 | 707 | 301 |
| Other costs associated with pazopanib and sunitinib treatmenta | 9,147 | 12,381 | -3,234 |
| Preprogression routine follow-up | 29,926 | 30,365 | -439 |
| Postprogression routine follow-up | 46,269 | 43,460 | 2,809 |
| Total | 154,559 | 161,387 | -6,828 |
| Incremental cost per QALY gained, $ | Dominant | ||
| NMB by threshold for cost-effectiveness, $ | |||
| $50,000 per QALY gained | 11,343 | ||
| $100,000 per QALY gained | 15,857 | ||
| $200,000 per QALY gained | 24,886 | ||
a Based on medical resource utilization data from the Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib (COMPARZ) study.
NMB = net monetary benefit; QALY = quality-adjusted life-year.